Newsroom

Third quarter revenue of $13.1 million, representing 98% growth YoY   Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025.

CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary,

CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to

Q2’25 revenue of $12.1 million , 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif. , Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions,

CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025.

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo ® cervical procedure on July 14, 2025 by Joseph

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 22, 2025-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock.

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that it has publicly filed a registration statement on Form S-1 with the U.S.

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo ® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced today that in the Hospital Inpatient Prospective Payment System Final Rule for fiscal year 2025, the Centers for Medicare & Medicaid Services (CMS) assigned spinal fusion cases with aprevo ®

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners. These proceeds will be used to accelerate the commercialization of the aprevo ® personalized spine

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that new clinical data on its aprevo ® technology has been published in the Global Spine Journal. This landmark study of a patient-matched cohort concluded that the use of aprevo ® personalized interbody devices enables a significant

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that the FDA granted Breakthrough Device designation for its aprevo® technology for treatment of patients with cervical spine disease. This is Carlsmed’s second Breakthrough Device designation, complementing the company’s family of